Veru Inc (VERU)

NASDAQ
5.500
+0.020(+0.36%)
After Hours
5.490
-0.010(-0.182%)
- Real-time Data
  • Volume:
    2,852,075
  • Day's Range:
    5.400 - 5.630
  • 52 wk Range:
    4.340 - 24.550
Earnings results expected tomorrow

Veru will announce its quarterly financial results tomorrow. Traders should take this into account as the share price often fluctuates around this time period.

VERU Overview

Prev. Close
5.48
Day's Range
5.4-5.63
Revenue
52.42M
Open
5.5
52 wk Range
4.34-24.55
EPS
-0.588
Volume
2,852,075
Market Cap
440.81M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
5,541,834
P/E Ratio
-25.31
Beta
-0.403
1-Year Change
-9.24%
Shares Outstanding
80,146,735
Next Earnings Date
Dec 05, 2022
What is your sentiment on Veru?
or
Market is currently closed. Voting is open during market hours.

Veru Inc News

Veru Inc Analysis

Veru Inc Company Profile

Veru Inc Company Profile

Employees
252

Veru Inc., a biopharmaceutical company, focuses on developing medicines for the management of breast and prostate cancers. Its commercial products comprise FC2 female condom/internal condom for the protection against unintended pregnancy and the transmission of sexually transmitted infections; and Entadfi, a capsule for the treatment of urinary tract symptoms. The company’s drug candidates under development include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase 2b clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral cytoskeleton disruptor plus selective androgen receptor agonist that is in phase 2b clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase 3 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase 2b clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Read More

Analyst Price Target

Average24.250 (+340.91% Upside)
High36
Low10
Price5.5
No. of Analysts4
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralBuyBuyStrong SellSell
Technical IndicatorsSellStrong BuyBuyStrong SellStrong Sell
SummaryNeutralStrong BuyBuyStrong SellStrong Sell
  • This has a huge potential
    1